Unknown

Dataset Information

Janus kinases inhibitors for coronavirus disease-2019: A pairwise and Bayesian network meta-analysis.


ABSTRACT:

Background

JAK (Janus kinases) inhibitors have been proposed as a promising treatment option for the coronavirus disease-2019 (COVID-19). However, the benefits of JAK inhibitors and the optimum thereof for COVID-19 have not been adequately defined.

Methods

Databases were searched from their inception dates to 17 June 2022. Eligible studies included randomized controlled trials and observational studies. Extracted data were analyzed by pairwise and network meta-analysis. The primary outcome was the coefficient of mortality.

Results

Twenty-eight studies of 8,206 patients were included and assessed qualitatively (modified Jadad and Newcastle-Ottawa Scale scores). A pairwise meta-analysis revealed that JAK inhibitors effectively reduced the mortality (OR = 0.54; 95% CI: 0

SUBMITTER: Niu J 

PROVIDER: S-EPMC9727257 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature